| 5.53 -0.26 (-4.49%) | 07-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.17  |
1-year : | 8.37 |
| Resists | First : | 6.13 |
Second : | 7.17 |
| Pivot price | 5.2 |
|||
| Supports | First : | 4.83 |
Second : | 4.03 |
| MAs | MA(5) : | 5.71 |
MA(20) : | 5.03 |
| MA(100) : | 3.49 |
MA(250) : | 4.1 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 86.8 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 6.67 | Low : | 1.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TKNO ] has closed below upper band by 35.2%. Bollinger Bands are 86.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.14 - 6.18 | 6.18 - 6.22 |
| Low: | 5.26 - 5.3 | 5.3 - 5.33 |
| Close: | 5.48 - 5.54 | 5.54 - 5.59 |
Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
Sun, 28 Jun 2026
Enterprise value to revenue forward of Alpha Teknova, Inc. – NASDAQ:TKNO - TradingView
Fri, 26 Jun 2026
TKNO Stock Price and Chart — NASDAQ:TKNO - TradingView
Tue, 02 Jun 2026
Alpha Teknova (TKNO) director gets 55,000 options at $5.37 strike - Stock Titan
Tue, 02 Jun 2026
Alpha Teknova (NASDAQ: TKNO) director awarded 55,000 non-qualified stock options - Stock Titan
Thu, 28 May 2026
TKNO - Alpha Teknova Inc Stock Price and Quote - Finviz
Sat, 09 May 2026
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.3 (%) |
| Held by Institutions | 84.7 (%) |
| Shares Short | 980 (K) |
| Shares Short P.Month | 1,270 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | -41.1 % |
| Operating Margin | -38.8 % |
| Return on Assets (ttm) | -9.3 % |
| Return on Equity (ttm) | -24 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 0.26 |
| Sales Per Share | 0.77 |
| EBITDA (p.s.) | -0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -17.84 |
| PEG Ratio | 0 |
| Price to Book value | 4.57 |
| Price to Sales | 7.09 |
| Price to Cash Flow | -37.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|